Dr Shirin Kalimuddin is clinically trained as an infectious disease specialist and currently holds the position of Consultant with the Department of Infectious Diseases at the Singapore General Hospital (SGH). She is also an Assistant Professor with the Emerging Infectious Diseases programme, Duke-NUS Medical School (Duke-NUS).

Dr Kalimuddin is currently at the forefront of clinical trials to study the safety and efficacy of therapeutics, for the treatment of COVID-19. She is also engaged in research to study the role of virological and host factors in determining COVID-19 outcome.

Her research spans basic, translational and clinical sciences. She investigates the role of the gut microbiome in the development of antibiotic-associated gastrointestinal adverse effects. She also studies the application of advanced imaging techniques on dengue patients to define sites of inflammation and plasma leakage. As a member of the Singapore Infectious Disease Clinical Research Network Executive Council, she is also actively involved in several clinical trials studying optimal therapeutic management for MRSA, Klebsiella and multidrug-resistant gram-negative bacterial infections.

In 2019, Dr Kalimuddin was awarded the NMRC Transition Award.